Indications › Cardiovascular disease

GLP‑1 drugs in cardiovascular disease

Which incretin agents are being studied in cardiovascular disease, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file

56

Active

26

Results scheduled

12

Molecules studied

9

Sponsors

48

FDA-approved for cardiovascular disease: dulaglutide · liraglutide · semaglutide · tirzepatide. Approval wording is on each drug page, quoted from the label.

4 of the molecules tracked here are FDA-approved for cardiovascular disease, so the trials below are asking further questions rather than establishing whether the class works at all. 47 of the 56 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 9 still in early phases. 48 distinct sponsors are involved, 8 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

dulaglutide · exenatide in this indication · liraglutide · maridebart cafraglutide · orforglipron · petrelintide · retatrutide · semaglutide in this indication · tirzepatide

Results due in this indication

Trials on file

All 56 incretin trials recorded in this indication, active first.